2025 Q4 -tulosraportti
87 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 min sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.
·4 t sittenIs there any substance to this comment I read recently? “I am very confident that the Q1 result will not only be positive, but will significantly exceed market expectations. Many are overlooking a large one-off gain: a provision of 4.2 billion dollars related to 'US 340B', which is expected to be reversed in Q1. It's strange that almost no one is talking about it. Although it is a one-off item, it is real bottom-line earnings that will easily outweigh concerns about price and volume.”
·2 t sittenBut if you know it, the big players know it too. And then it's priced in. Or do you expect that you are the only ones who know it?·17 min sittenSo, the thing about it being priced in isn't true. When the "pill" came out, people also said it was already priced in, but as I also wrote there, that was nonsense, because precisely when the "pill" came out, the stock exploded upwards; it wouldn't have done that if it had been priced in beforehand.
·5 t sitten · MuokattuI have been in the stock market for decades. That is precisely the situation the American stock market has been in in recent months. All seasoned investors know that an average P/E value over 20-25 is unrealistic in an economy that, due to uncontrollable growth in foreign debt, would sooner or later be forced to turn down the heat, as a competitiveness improvement through a further devaluation of the dollar apparently is not a practical option. Nevertheless, most buy in blind faith that the madness would continue. I sold my last US AI companies last Friday with a good profit. I couldn't care less that I don't get the last possibly 5-10 percent.- ·6 t sittenWhat is currently driving growth are the weight loss drugs Zepbound and Mounjaro, which are also used for diabetes, driving growth at Eli Lilly at the moment, and helped the company to raise its full-year growth forecast - despite drug prices having fallen 7 percent on average in the first quarter. The financial report largely underlines the continued difference between Eli Lilly and Novo Nordisk, as Lilly continues to deliver positive results compared to the much more optimistic growth prospects for a group of hormones worldwide, writes a pharmaceutical analyst from Bernstein in a comment. It will be exciting when Novo Nordisk publishes its first-quarter financial report on the morning of Wednesday, May 6, 2026.
·4 t sittenEli Lilly has faced further demands from the FDA due to side effects. Novo has a better product, which can be directly seen in the sales figures for the Novo pill. All doctors recommend Novo's pill. Who dares to take Eli Lilly's pill. I don't dare.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
87 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 min sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.
- ·4 t sittenIs there any substance to this comment I read recently? “I am very confident that the Q1 result will not only be positive, but will significantly exceed market expectations. Many are overlooking a large one-off gain: a provision of 4.2 billion dollars related to 'US 340B', which is expected to be reversed in Q1. It's strange that almost no one is talking about it. Although it is a one-off item, it is real bottom-line earnings that will easily outweigh concerns about price and volume.”·2 t sittenBut if you know it, the big players know it too. And then it's priced in. Or do you expect that you are the only ones who know it?·17 min sittenSo, the thing about it being priced in isn't true. When the "pill" came out, people also said it was already priced in, but as I also wrote there, that was nonsense, because precisely when the "pill" came out, the stock exploded upwards; it wouldn't have done that if it had been priced in beforehand.
- ·5 t sitten · MuokattuI have been in the stock market for decades. That is precisely the situation the American stock market has been in in recent months. All seasoned investors know that an average P/E value over 20-25 is unrealistic in an economy that, due to uncontrollable growth in foreign debt, would sooner or later be forced to turn down the heat, as a competitiveness improvement through a further devaluation of the dollar apparently is not a practical option. Nevertheless, most buy in blind faith that the madness would continue. I sold my last US AI companies last Friday with a good profit. I couldn't care less that I don't get the last possibly 5-10 percent.
- ·6 t sittenWhat is currently driving growth are the weight loss drugs Zepbound and Mounjaro, which are also used for diabetes, driving growth at Eli Lilly at the moment, and helped the company to raise its full-year growth forecast - despite drug prices having fallen 7 percent on average in the first quarter. The financial report largely underlines the continued difference between Eli Lilly and Novo Nordisk, as Lilly continues to deliver positive results compared to the much more optimistic growth prospects for a group of hormones worldwide, writes a pharmaceutical analyst from Bernstein in a comment. It will be exciting when Novo Nordisk publishes its first-quarter financial report on the morning of Wednesday, May 6, 2026.·4 t sittenEli Lilly has faced further demands from the FDA due to side effects. Novo has a better product, which can be directly seen in the sales figures for the Novo pill. All doctors recommend Novo's pill. Who dares to take Eli Lilly's pill. I don't dare.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
87 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,21%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 min sittenWhy are there always so many who write "it's priced in"? That's almost never true. When the pill came out, several wrote that it wouldn't affect the stock because everyone knew the pill was coming so it was priced in. To which I predicted that it wasn't true and that the stock would explode upwards, which it did, so that disproves all this "it's priced in" stuff.
- ·4 t sittenIs there any substance to this comment I read recently? “I am very confident that the Q1 result will not only be positive, but will significantly exceed market expectations. Many are overlooking a large one-off gain: a provision of 4.2 billion dollars related to 'US 340B', which is expected to be reversed in Q1. It's strange that almost no one is talking about it. Although it is a one-off item, it is real bottom-line earnings that will easily outweigh concerns about price and volume.”·2 t sittenBut if you know it, the big players know it too. And then it's priced in. Or do you expect that you are the only ones who know it?·17 min sittenSo, the thing about it being priced in isn't true. When the "pill" came out, people also said it was already priced in, but as I also wrote there, that was nonsense, because precisely when the "pill" came out, the stock exploded upwards; it wouldn't have done that if it had been priced in beforehand.
- ·5 t sitten · MuokattuI have been in the stock market for decades. That is precisely the situation the American stock market has been in in recent months. All seasoned investors know that an average P/E value over 20-25 is unrealistic in an economy that, due to uncontrollable growth in foreign debt, would sooner or later be forced to turn down the heat, as a competitiveness improvement through a further devaluation of the dollar apparently is not a practical option. Nevertheless, most buy in blind faith that the madness would continue. I sold my last US AI companies last Friday with a good profit. I couldn't care less that I don't get the last possibly 5-10 percent.
- ·6 t sittenWhat is currently driving growth are the weight loss drugs Zepbound and Mounjaro, which are also used for diabetes, driving growth at Eli Lilly at the moment, and helped the company to raise its full-year growth forecast - despite drug prices having fallen 7 percent on average in the first quarter. The financial report largely underlines the continued difference between Eli Lilly and Novo Nordisk, as Lilly continues to deliver positive results compared to the much more optimistic growth prospects for a group of hormones worldwide, writes a pharmaceutical analyst from Bernstein in a comment. It will be exciting when Novo Nordisk publishes its first-quarter financial report on the morning of Wednesday, May 6, 2026.·4 t sittenEli Lilly has faced further demands from the FDA due to side effects. Novo has a better product, which can be directly seen in the sales figures for the Novo pill. All doctors recommend Novo's pill. Who dares to take Eli Lilly's pill. I don't dare.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 54 | - | - | ||
| 400 | - | - | ||
| 100 | - | - | ||
| 240 | - | - | ||
| 163 | - | - |
Välittäjätilasto
Dataa ei löytynyt